{"id":82792,"topic":"peptides","source":"Fierce Biotech","title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","url_hash":"c7dd2513aeea8dcce74c8ff74ed632b4bc5e7a8d","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5\" target=\"_blank\">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>","content":null,"image_url":null,"lang":"en","published_at":"2026-09-15T08:47:22+00:00","fetched_at":"2026-09-15T10:15:09+00:00","status":"read","starred":0,"extract_state":"failed","summary_auto":null,"cluster_id":null,"extract_retries":2,"extract_error":"http_403","contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":458,"usable_text_length":458,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":458}},"news_item":{"id":82792,"canonical_url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","source_url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","source_name":"Fierce Biotech","author":null,"published_at":"2026-09-15T08:47:22+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5\" target=\"_blank\">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>","full_text":null,"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5\" target=\"_blank\">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>","extraction":{"state":"failed","confidence":0.0,"error":"http_403","explanation":"Low confidence: HTTP extraction failure (http_403).","diagnostics_url":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":458,"usable_text_length":458,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":458}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","summary":"<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5\" target=\"_blank\">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>","source":"Fierce Biotech","date":"2026-09-15T08:47:22+00:00","content":"","confidence":0.0,"diagnostics_url":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","quality_bucket":"failed","failure_kind":"http","retryable":false,"quality_reason":"Low confidence: HTTP extraction failure (http_403).","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":458,"usable_text_length":458,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":458}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/82792","export_markdown":"/api/items/82792/export?format=markdown","export_json":"/api/items/82792/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic"},"formats":{"full":{"id":82792,"title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","source":"Fierce Biotech","author":null,"published_at":"2026-09-15T08:47:22+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5\" target=\"_blank\">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>","full_text":null,"reading_time_min":1,"extraction":{"state":"failed","confidence":0.0,"error":"http_403","explanation":"Low confidence: HTTP extraction failure (http_403).","diagnostics_url":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":458,"usable_text_length":458,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":458}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":458,"usable_text_length":458,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":458}},"actions":{"read":"/item/82792","export_markdown":"/api/items/82792/export?format=markdown","export_json":"/api/items/82792/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic"}},"digest":{"id":82792,"title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","source":"Fierce Biotech","topic":"peptides","published_at":"2026-09-15T08:47:22+00:00","excerpt":"<a…","quality_bucket":"failed","quality_reason":"Low confidence: HTTP extraction failure (http_403).","reading_time_min":1,"cluster_id":null},"card":{"display_title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","subtitle":"Fierce Biotech · 2026-09-15","summary":"<a…","badges":["quality:failed","issue:http"],"links":{"read":"/item/82792","original":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","diagnose":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic"},"quality_warning":"Low confidence: HTTP extraction failure (http_403)."},"export":{"title":"Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide - Fierce Biotech","url":"https://www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","summary":"<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWnRlUmM0cGJMN2J0dHZsUnNEbjBDRmRMZ1VqQ2M0OVJncERIY3BrTFo4TS1aYjNjeXhMUDc3cTBYZ2hQU05GNDdsczFldmZNR0NuQXpaTnd4S1hXMkMzcmU0S3MxWG55RFBxVHBocDdaSklWSUh3RXRjeWM3bGZzeUZEZ0d0RWZJVER6ZDF0UTgtZDNycVZFQTRjWklqSHNrUDU2NFNvcWlDV3Zzc0E?oc=5\" target=\"_blank\">Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>","source":"Fierce Biotech","date":"2026-09-15T08:47:22+00:00","content":"","confidence":0.0,"diagnostics_url":"/api/diagnose?url=https%3A//www.fiercebiotech.com/biotech/axoltis-misses-mark-phase-2-als-study-still-strives-move-towards-clinic","quality_bucket":"failed","failure_kind":"http","retryable":false,"quality_reason":"Low confidence: HTTP extraction failure (http_403).","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"failed","confidence":0.0,"failure_kind":"http","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: HTTP extraction failure (http_403).","operator_guidance":{"severity":"action_required","recommended_action":"manual_review","next_step":"Open diagnostics and review the original source manually before use.","operator_label":"Manual review","can_retry":false,"can_use_summary":false,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":458,"usable_text_length":458,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"http_403","extract_retries":2,"content_length":0,"summary_length":458}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}